ResMed Inc. announced robust results for the second quarter of fiscal year 2026, with revenue increasing by 11% to $1.4228 billion and diluted earnings per share rising by 15% to $2.68. Non-GAAP diluted earnings per share also saw a 16% increase to $2.81, driven by strong sales growth and gross margin improvement.

ResMed delivered a strong start to fiscal year 2026, with revenue increasing 9% to $1.3 billion and non-GAAP diluted EPS growing 16% to $2.55. The company saw significant gross margin expansion due to manufacturing efficiencies and component cost improvements, reinforcing its strategy to transform healthcare in the home.

ResMed concluded fiscal year 2025 with a robust fourth quarter, driven by strong global demand for sleep and breathing health devices and an expanding digital health ecosystem. The company achieved double-digit revenue growth and significant improvements in gross margin and earnings per share.

ResMed delivered a solid third quarter for FY2025, with revenue reaching $1.29 billion, driven by sustained demand across devices, masks, and SaaS offerings. The company saw improvements in gross margins and profitability, supported by efficient operations and favorable product mix.

ResMed Inc. reported a 10% increase in revenue to $1.3 billion, a 52% increase in operating profit, and a 19% increase in non-GAAP operating profit for the second quarter of fiscal year 2025. The company's diluted earnings per share was $2.34, with a non-GAAP diluted earnings per share of $2.43. Operating cash flow was $309 million.

ResMed reported an 11% increase in revenue, a 34% increase in operating profit, and a non-GAAP operating profit increase of 27%. The company's focus on operational excellence led to margin expansion. They are celebrating 35 years of growth and innovation, with a newly launched 2030 strategy to transform sleep health, breathing health, and healthcare technology at home.

ResMed Inc. reported a 9% increase in revenue to $1.2 billion for the fourth quarter of fiscal year 2024. The company's operating profit increased by 38%, with non-GAAP operating profit up by 30%. Diluted earnings per share were reported at $1.98, and non-GAAP diluted earnings per share at $2.08.

ResMed reported a 7% increase in revenue to $1.2 billion, a 25% increase in operating profit, and a 29% increase in net income. Diluted earnings per share were $2.04, and non-GAAP diluted earnings per share were $2.13.

ResMed Inc. reported a 12% increase in revenue to $1.2 billion for the second quarter of fiscal year 2024. Diluted earnings per share were $1.42, and non-GAAP diluted earnings per share were $1.88. The company saw strong growth across its device, masks and accessories, and residential care software businesses.

ResMed Inc. reported a 16% increase in revenue to $1.1 billion for the first quarter of fiscal year 2024. The company saw growth across global sleep and respiratory care markets and increased adoption of outside hospital software solutions. Diluted earnings per share were reported at $1.49, with non-GAAP diluted earnings per share at $1.64.

ResMed Inc. reported a 23% increase in revenue to $1.1 billion for the fourth quarter of fiscal year 2023. Diluted earnings per share were $1.56, and non-GAAP diluted earnings per share were $1.60. The company's performance was driven by strong global demand for its cloud-connected flow generator devices, patient interfaces, and software solutions.

ResMed Inc. reported a strong third quarter in fiscal year 2023, marked by a 29% increase in revenue to $1,116.9 million and a 28% rise in operating profit. The company saw robust growth in device sales, driven by increased production and delivery of cloud-connected flow generator devices, as well as strong performance in mask and patient interfaces businesses. The Software-as-a-Service (SaaS) business also contributed significantly with a 35% revenue increase.

ResMed Inc. reported a 16% increase in revenue to $1,033.7 million and a diluted earnings per share of $1.53 for the second quarter of fiscal year 2023. The company's performance was driven by increased production and delivery of flow generator devices to meet customer demand and the acquisition of MEDIFOX DAN.

ResMed Inc. reported a 5% increase in revenue to $950.3 million, with a diluted earnings per share of $1.43 and non-GAAP diluted earnings per share of $1.51.

ResMed Inc. reported a 4% increase in revenue, reaching $914.7 million, and a 6% rise in operating profit for the fourth quarter of fiscal year 2022. The company's diluted earnings per share stood at $1.33, while non-GAAP diluted earnings per share reached $1.49.

ResMed Inc. reported a 12% increase in revenue to $864.5 million for the quarter ended March 31, 2022. Diluted earnings per share were $1.22, and non-GAAP diluted earnings per share were $1.32.

ResMed Inc. announced results for the quarter ended December 31, 2021. Revenue increased by 12% to $894.9 million, and diluted earnings per share were $1.37.

ResMed Inc. reported a 20% increase in revenue to $904.0 million and a 21% increase in operating profit for the first quarter of fiscal year 2022. The company's performance was driven by high demand for sleep and respiratory care products and steady growth in its software-as-a-service business, despite ongoing supply chain challenges.

ResMed Inc. reported a 14% increase in revenue to $876.1 million for the fourth quarter of fiscal year 2021. Diluted earnings per share were $1.33, and non-GAAP diluted earnings per share were $1.35. The company saw recovery in core sleep apnea and COPD patient flow and benefited from a competitor's product recall.

ResMed reported comparable revenue of $768.8 million, but experienced a net loss of $78.5 million, or $(0.54) per share, due to a $255 million reserve for a tax dispute with the Australian Tax Office. Excluding COVID-19 revenue from the prior year, revenue increased by 1% on a constant currency basis. Non-GAAP diluted EPS was $1.30. The company is optimistic about future growth, driven by increased awareness of respiratory health and adoption of digital health solutions.

ResMed Inc. reported a 9% increase in revenue to $800.0 million for the second quarter of fiscal year 2021. GAAP diluted earnings per share were $1.23, and non-GAAP diluted earnings per share were $1.41. The company saw growth in its core markets and adoption of digital health solutions.

ResMed Inc. reported a 10% increase in revenue to $751.9 million and a 24% increase in non-GAAP operating profit for the first quarter of fiscal year 2021. The company continued to support the global COVID-19 pandemic response and saw sequential improvement in new patient volume in core markets.

ResMed Inc. reported a 9% increase in revenue to $770.3 million for the fourth quarter of fiscal year 2020. Non-GAAP diluted earnings per share were $1.33, a 40% increase compared to the prior year period. The company saw strong sales across its mask product portfolio and increased demand for ventilators due to COVID-19.

ResMed Inc. reported a 16% increase in revenue to $769.5 million for the third quarter of fiscal year 2020. Non-GAAP operating profit increased by 31%. The company is focused on combating the COVID-19 pandemic through increased ventilator production.

ResMed reported a strong December quarter with double-digit top-line growth and gross margin expansion. Revenue increased by 13% to $736.2 million, and non-GAAP operating profit was up by 21%. The company saw continued strong customer demand for new products, particularly in masks and accessories.